Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas
Neuro-Oncology · 03.10.2023 · 25 (10) · 1883-1894
DOI: 10.1093/neuonc/noad086 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Neuro-Oncology, online erschienen am 28.04.2023. Verfasst von Andrea M Gross und 18 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Neurofibromatosis 1, Neurofibroma, Plexiform. Die Arbeit wurde bisher 113-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, CCR NIH HHS, NIH HHS.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Selumetinib shrank inoperable symptomatic plexiform neurofibromas (PN) in children with neurofibromatosis type 1 (NF1) and provided clinical benefit for many in our previously published phase 1/2 clinical trials (SPRINT, NCT01362803). At the data cutoff (DCO) of the prior publications, 65% of participants were still receiving treatment. This report presents up to 5 years of additional safety and efficacy data from these studies.
Methods
This manuscript includes data from the phase 1 and phase 2, stratum 1 study which included participants with clinically significant PN-related morbidity. Participants received continuous selumetinib dosing (1 cycle = 28 days). Safety and efficacy data through February 27, 2021 are included. PN response assessed by volumetric magnetic resonance imaging analysis: Confirmed partial response (cPR) ≥20% decrease from baseline on 2 consecutive evaluations. Phase 2 participants completed patient-reported outcome measures assessing tumor pain intensity (Numeric Rating Scale-11) and interference of pain in daily life (pain interference index).
Results
For the 74 children (median age 10.3 years; range 3–18.5) enrolled, overall cPR rate was 70% (52/74); median duration of treatment was 57.5 cycles (range 1–100). Responses were generally sustained with 59% (44) lasting ≥ 12 cycles. Tumor pain intensity (n = 19, P = .015) and pain interference (n = 18, P = .0059) showed durable improvement from baseline to 48 cycles. No new safety signals were identified; however, some developed known selumetinib-related adverse events (AEs) for the first time after several years of treatment.
Conclusions
With up to 5 years of additional selumetinib treatment, most children with NF1-related PN had durable tumor shrinkage and sustained improvement in pain beyond that previously reported at 1 year. No new safety signals were identified; however, ongoing monitoring for known selumetinib-related AEs is needed while treatment continues.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
- Leidos, Clinical Research Directorate (CRD), Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
- Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA.
- Children's Hospital of Philadelphia, Section of Neuro-Oncology, Philadelphia, Pennsylvania, USA.
- Children's National Hospital, Center for Cancer and Blood Disorders, Washington, District of Columbia, USA.
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
ORCID-Profile: Andrea M Gross, Eva Dombi, Seth M Steinberg, AeRang Kim, Miriam Bornhorst, Jaishri O Blakeley, Brigitte C Widemann
Förderung
- NCI NIH HHS
- CCR NIH HHS
- NIH HHS
- National Institutes of Health
- Center for Cancer Research
- National Cancer Institute
- Cancer Therapy Evaluation Program
Zitieren
APA
Gross, A. M., Dombi, E., Wolters, P. L., Baldwin, A., Dufek, A., Herrera, K., Martin, S., Derdak, J., Heisey, K. S., Whitcomb, P. M., Steinberg, S. M., Venzon, D. J., Fisher, M. J., Kim, A., Bornhorst, M., Weiss, B. D., Blakeley, J. O., Smith, M. A., & Widemann, B. C. (2023). Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas. Neuro-Oncology, 25(10), 1883-1894. https://doi.org/10.1093/neuonc/noad086
Vancouver
Gross AM, Dombi E, Wolters PL, Baldwin A, Dufek A, Herrera K, et al. Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas. Neuro-Oncology. 2023;25(10):1883-1894. doi:10.1093/neuonc/noad086
BibTeX
@article{Gross2023,
author = {Gross, Andrea M and Dombi, Eva and Wolters, Pamela L and Baldwin, Andrea and Dufek, Anne and Herrera, Kailey and Martin, Staci and Derdak, Joanne and Heisey, Kara S and Whitcomb, Patricia M and Steinberg, Seth M and Venzon, David J and Fisher, Michael J and Kim, AeRang and Bornhorst, Miriam and Weiss, Brian D and Blakeley, Jaishri O and Smith, Malcolm A and Widemann, Brigitte C},
title = {Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas},
journal = {Neuro-Oncology},
year = {2023},
volume = {25},
number = {10},
pages = {1883--1894},
doi = {10.1093/neuonc/noad086}
}
EUVIMED